Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for maintenance of remission in pediatric UC
NCT05316220Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Salcrozine in ulcerative colitis (UC), sponsored by AbbVie Inc.. Planned start Sep 2025; status: withdrawn.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05316220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316220.